Skip to main content
. 2022 Jan 27;14(1):140–157. doi: 10.4254/wjh.v14.i1.140

Figure 2.

Figure 2

Immunotherapy in hepatocellular carcinoma: Potential strategies and therapeutic targets. IR: Immune response; PD-1: Programmed cell death protein 1; PD-L1: Programmed death-ligand 1; CTLA-4: Cytotoxic T-lymphocyte associated antigen 4; TGF-β: Transforming growth factor-beta; LAG3: Lymphocyte-activation gene 3; CIK: Cytokine-induced killer; TIL: Tumor-infiltrating lymphocyte; NK: Natural killer; DC: Dendritic cell; GPC3: Glypican-3.